发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Patents, pharmaceutical industry and healthcare. 专利，制药工业和医疗保健。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-03-01 DOI: 10.4155/ppa-2023-0009
Ruqaiyyah Siddiqui, Naveed A Khan
{"title":"Patents, pharmaceutical industry and healthcare.","authors":"Ruqaiyyah Siddiqui, Naveed A Khan","doi":"10.4155/ppa-2023-0009","DOIUrl":"https://doi.org/10.4155/ppa-2023-0009","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 2","pages":"57-60"},"PeriodicalIF":1.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9684984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent landscape highlighting double-edged scaffold of a WNT5A-agonizing peptide, Foxy5. 专利景观突出wnt5a痛苦肽Foxy5的双刃支架。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-03-01 DOI: 10.4155/ppa-2022-0037
Vikas Yadav, Rubina Islam, Hardeep Singh Tuli
{"title":"Patent landscape highlighting double-edged scaffold of a WNT5A-agonizing peptide, Foxy5.","authors":"Vikas Yadav,&nbsp;Rubina Islam,&nbsp;Hardeep Singh Tuli","doi":"10.4155/ppa-2022-0037","DOIUrl":"https://doi.org/10.4155/ppa-2022-0037","url":null,"abstract":"<p><p>Aberrant expression of the WNT signaling pathway has been associated with cancer progression and recurrence. Research over the decades has led to development of WNT-targetable small molecules, but has faced challenges in translating to clinics. Unlike WNT/β-catenin inhibitors, WNT5A-mimicking peptide, Foxy5 has shown encouraging efficacy in impairing metastasis of cancers with low or absent WNT5A expression. Recent patent application US20210008149 advocates the implication of Foxy5 for treatment and prevention of cancer relapse. The inventors have demonstrated the anti-stemness activity of Foxy5 in mice xenograft model via suppressing the expression of colonic cancer stem cell markers. Foxy5 also exhibits non-toxic nature when administered alone or in synergy with standard chemotherapy thus strengthening its candidature in the field of cancer therapeutics.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 2","pages":"69-77"},"PeriodicalIF":1.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9616404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of EPO Board of Appeal antibody decisions in 2022. 2022年对欧洲专利局上诉委员会抗体决定的复审。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-03-01 DOI: 10.4155/ppa-2023-0014
Daniel Hilton, Vicki Allen, Graham Lewis
{"title":"Review of EPO Board of Appeal antibody decisions in 2022.","authors":"Daniel Hilton,&nbsp;Vicki Allen,&nbsp;Graham Lewis","doi":"10.4155/ppa-2023-0014","DOIUrl":"https://doi.org/10.4155/ppa-2023-0014","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 2","pages":"51-55"},"PeriodicalIF":1.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents. 4-(咪唑并[1,2-a]吡啶-3-基)：作为抗癌剂的嘧啶衍生物。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 Epub Date: 2022-11-10 DOI: 10.4155/ppa-2022-0033
Rami A Al-Horani
{"title":"4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.","authors":"Rami A Al-Horani","doi":"10.4155/ppa-2022-0033","DOIUrl":"10.4155/ppa-2022-0033","url":null,"abstract":"<p><p>A series of 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives are claimed as inhibitors of c-KIT and as potential treatments for cancer. Their chemical preparation and biological evaluation against imatinib-resistant tumor cells have been described. Several claimed molecules have excellent IC<sub>50</sub> values in the nanomolar range. Several molecules were also selective against a wide panel of kinases. Few specific inhibitors have been found to have promising oral bioavailability and acceptable to excellent values regarding the inhibition of hERG channel. This class represents a new platform for developing new anticancer treatment against a wide range of c-KIT mutations and secondary mutations that may arise in gastrointestinal stromal tumor patients.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"13-18"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances. 光反应性脂质体:用于检测少量目标物质的ELISA替代方法。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 DOI: 10.4155/ppa-2022-0046
Ramesh Joga, Hitesh Kumar Behera, Chetan Dushant Sabanis, Simran, Sandeep Kumar, Neeraj Kumar
{"title":"Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances.","authors":"Ramesh Joga,&nbsp;Hitesh Kumar Behera,&nbsp;Chetan Dushant Sabanis,&nbsp;Simran,&nbsp;Sandeep Kumar,&nbsp;Neeraj Kumar","doi":"10.4155/ppa-2022-0046","DOIUrl":"https://doi.org/10.4155/ppa-2022-0046","url":null,"abstract":"<p><p>Photoresponsive liposome development is needed to serve as a facile alternative to ELISA which is ineffective for detecting small levels of biomarkers due to low detection sensitivity. The US20210396744 patent application outlines novel photoresponsive liposomes for the detection of target substances with the aid of light. Although versatile, there may be possible stability issues that can be avoided with the appropriate selection of liposome components. Furthermore, the clinical success of this technology depends on many parameters like plasma stability, efficient loading of photosensitive components in the membrane and immobilization of molecular recognition elements to the membrane. Despite several challenges, they possess enormous potential to become a non-invasive tool for the detection of target substances.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"27-35"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9579358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Patent developments via Schiff bases in medicinal chemistry. 药物化学中希夫碱基的专利开发。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 DOI: 10.4155/ppa-2022-0045
Maham Haider, Khalid Mohammed Khan
{"title":"Patent developments <i>via</i> Schiff bases in medicinal chemistry.","authors":"Maham Haider,&nbsp;Khalid Mohammed Khan","doi":"10.4155/ppa-2022-0045","DOIUrl":"https://doi.org/10.4155/ppa-2022-0045","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"1-3"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights June-July 2022. 专利亮点2022年6月至7月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 DOI: 10.4155/ppa-2022-0043
Hermann Am Mucke
{"title":"Patent Highlights June-July 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0043","DOIUrl":"https://doi.org/10.4155/ppa-2022-0043","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"5-11"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9236934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-processed tablet excipient composition, its preparation and use: US10071059 B2: patent spotlight. 共加工片剂辅料组成，其制备及用途:US10071059 B2:专利聚光灯。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 DOI: 10.4155/ppa-2022-0036
Sajal Jain, Ritu Rathi, Upendra Nagaich, Inderbir Singh
{"title":"Co-processed tablet excipient composition, its preparation and use: US10071059 B2: patent spotlight.","authors":"Sajal Jain,&nbsp;Ritu Rathi,&nbsp;Upendra Nagaich,&nbsp;Inderbir Singh","doi":"10.4155/ppa-2022-0036","DOIUrl":"https://doi.org/10.4155/ppa-2022-0036","url":null,"abstract":"<p><p>Co-processing involves the incorporation of one excipients into the particle structure of other excipients to overcome the deficiencies of each excipients. The current patent describes the co-processing of microcrystalline cellulose and mannitol via fluid bed agglomeration with an aim to limit the use of lubricant in tablet composition. The co-processed excipients blend was compared with the physical blend of excipients and characterized for scanning electron microscopy, disintegration and hardness. The average particle size of co-processed excipients was less than 0.55 mm, characterized by large individual lactose-coated particles whereas, the physical blend particles are uncoated and irregular in shape. Tablets made from both physical blend and co-processed excipients were compared. As per the hardness and disintegration studies, with increase in mixing time of excipients both hardness and disintegration time decreases.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"19-25"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9214979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patenting trends in the pharmaceutical field of Mexican universities. 墨西哥大学制药领域的专利趋势。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-01-01 DOI: 10.4155/ppa-2022-0048
Gabriela Sanchez-Esgua, Juan Reyes-Alvarez, Martin Perez-Santos
{"title":"Patenting trends in the pharmaceutical field of Mexican universities.","authors":"Gabriela Sanchez-Esgua,&nbsp;Juan Reyes-Alvarez,&nbsp;Martin Perez-Santos","doi":"10.4155/ppa-2022-0048","DOIUrl":"https://doi.org/10.4155/ppa-2022-0048","url":null,"abstract":"<p><p><b>Aim</b>: pharmaceutical patenting activity in developing countries, including Mexico, is unknown. <b>Objective</b>: determine the activity of pharmaceutical patents by Mexican universities. <b>Method</b>: using 'university' as keyword and A61K, A61P and C07 as International Patent Classification codes, was searched to generate a perspective of pharmaceutical patent applications by Mexican universities. <b>Results</b>: 227 patents (186 granted patents + 41 not-granted patents) were claimed in the period 2000-2018. The leading university was the National Autonomous University of Mexico, followed by the Instituto Politecnico Nacional, Universidad Autonoma de Nuevo León and Universidad Autonoma de Puebla. The pharmaceutical concerns addressed were led by the fields of infectious, cancer and diabetes. <b>Conclusion</b>: in Mexican universities, the licensing of pharmaceutical patents is still in its early stages.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 1","pages":"37-50"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9563125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral insulin delivery: a patent review. 口服胰岛素:专利审查。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0017
Shivani Sharma, Amit Mittal, Anuradha Mehra
{"title":"Oral insulin delivery: a patent review.","authors":"Shivani Sharma,&nbsp;Amit Mittal,&nbsp;Anuradha Mehra","doi":"10.4155/ppa-2022-0017","DOIUrl":"https://doi.org/10.4155/ppa-2022-0017","url":null,"abstract":"<p><p>Insulin, on oral administration, is very troublesome because of its limited bioavailability. The evolution of oral insulin delivery formulations is greatly desired for non-invasive therapy by overcoming its low bioavailability, GIT enzymatic deactivation, poor lipophilicity and low stability. Different approaches have been proposed to boost oral insulin bioavailability in insulin-delivery systems and emerging effective therapies by using nanoparticle formulation, nanocapsid, modified chitosan particles, polydopamine microcapsules and nanoliposomes. The present review includes patents and patent applications that were published between 2017 and January 2022.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"199-212"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9158325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信